This study accomplished three goals: (a) completed the first study measuring serum sphingolipids in LGL leukemia, (b) compared the two LGL leukemia subtypes in one study to find biomarker differences between the two subtypes, and (c) established relationships between specific STAT3 mutations and clinical data. Here, STAT3 is linked to T-cell large granular lymphocyte leukemia.